KDOQI/KDIGO Guidelines for CAPD Monitoring and Management
Yes, KDOQI provides comprehensive guidelines for monitoring and managing continuous ambulatory peritoneal dialysis (CAPD) patients, with specific recommendations for solute clearance targets, measurement frequency, and residual kidney function assessment 1, 2.
Core Monitoring Requirements
Solute Clearance Targets
The minimal delivered dose of total small-solute clearance must be a total (peritoneal and kidney) Kt/V urea of at least 1.7 per week 1. This represents a critical downward revision from the previous target of 2.0, based on randomized controlled trial evidence (ADEMEX and Hong Kong studies) showing no survival benefit from higher peritoneal clearances 1.
Measurement Frequency
The KDOQI guidelines establish a clear monitoring algorithm 1:
- Initial assessment: Measure total solute clearance (Kt/V urea) within the first month after initiating dialysis
- Ongoing monitoring: Reassess at least once every 4 months thereafter
- Residual kidney function monitoring: If urine volume >100 mL/day, obtain 24-hour urine collection for volume and solute clearance determinations at minimum every 2 months
Critical Distinction: Residual Kidney Function
Residual kidney function (RKF) is more important than peritoneal clearance for patient survival 1. The reanalysis of the CANUSA Study and subsequent ADEMEX trial demonstrated that RKF, rather than peritoneal clearance, was the primary predictor of survival. This fundamentally changed the approach to CAPD adequacy assessment.
Practical Implementation
For Patients WITH Significant RKF (>100 mL/day urine):
- Target total Kt/V urea ≥1.7/week (combined peritoneal + kidney clearance)
- Monitor urine collections every 2 months minimum
- Preserve RKF aggressively as it provides survival benefit beyond just clearance numbers
For Patients WITHOUT Significant RKF (≤100 mL/day urine):
- Target peritoneal Kt/V urea ≥1.7/week alone
- Standard 4-month monitoring intervals sufficient
Important Caveats
These are MINIMAL targets, not optimal targets 2. The shift from "target" to "minimal dose" means less margin for error—all patients must be above this threshold. The guidelines explicitly warn that using minimal doses requires more vigilance than the previous target-based approach.
The evidence base comes from relatively short-term trials in Mexico and Hong Kong populations 2, which may have different protein intakes and adherence patterns than typical U.S. patients. Clinical judgment remains essential.
Additional KDOQI/KDIGO Resources
While the 2006 KDOQI PD Adequacy Guidelines 1, 2 remain the primary reference for CAPD monitoring, supplementary guidance exists for infection prevention and management 3 and anemia management 4, though these address different aspects of PD care.
The guidelines explicitly state they should inform but not replace clinical judgment, and discourage their use as rigid clinical performance measurements 2.